TAT-11: Lanthanide-based Nanoparticles for Multimodal Molecular Imaging and Targeted Alpha Therapy

Ottawa, ON, Canada (UroToday.com) One of the vexing problems in targeted alpha therapy is the release of daughters by the recoil of the first decay. One solution is to encapsulate the radioisotope in a nanoparticle shell. The shell thickness is chosen to be thin enough to allow the alphas to escape but thick enough to contain the much shorter range daughters. This study looks at Lanthanum based nanoparticles to accomplish this goal.

Adding two shells to a LaPO4 core enhanced retention—up to 99% retention of Th227 and Ac225 and daughters. Other nanoparticles based on LaVO4 also showed encouraging results.


Presented by: Mr. Miguel Toro-Gonzalez, Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe